T cell-based strategies for HIV-1 vaccines
Despite 30 years of effort, we do not have an effective HIV-1 vaccine. Over the past decade, the HIV-1 vaccine field has shifted emphasis toward antibody-based vaccine strategies, following a lack of efficacy in CD8+ T-cell-based vaccine trials. Several lines of evidence, however, suggest that impro...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-03-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2019.1666957 |
| _version_ | 1797677358869643264 |
|---|---|
| author | Bette Korber Will Fischer |
| author_facet | Bette Korber Will Fischer |
| author_sort | Bette Korber |
| collection | DOAJ |
| description | Despite 30 years of effort, we do not have an effective HIV-1 vaccine. Over the past decade, the HIV-1 vaccine field has shifted emphasis toward antibody-based vaccine strategies, following a lack of efficacy in CD8+ T-cell-based vaccine trials. Several lines of evidence, however, suggest that improved CD8+ T-cell-directed strategies could benefit an HIV-1 vaccine. First, T-cell responses often correlate with good outcomes in non-human primate (NHP) challenge models. Second, subgroup studies of two no-efficacy human clinical vaccine trials found associations between CD8+ T-cell responses and protective effects. Finally, improved strategies can increase the breadth and potency of CD8+ T-cell responses, direct them toward preferred epitopes (that are highly conserved and/or associated with viral control), or both. Optimized CD8+ T-cell vaccine strategies are promising in both prophylactic and therapeutic settings. This commentary briefly outlines some encouraging findings from T-cell vaccine studies, and then directly compares key features of some T-cell vaccine candidates currently in the clinical pipeline. |
| first_indexed | 2024-03-11T22:43:55Z |
| format | Article |
| id | doaj.art-99b53a937d754c8ea8fb4bedea06a13e |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:43:55Z |
| publishDate | 2020-03-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-99b53a937d754c8ea8fb4bedea06a13e2023-09-22T08:45:33ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2020-03-0116371372210.1080/21645515.2019.16669571666957T cell-based strategies for HIV-1 vaccinesBette Korber0Will Fischer1Los Alamos National LaboratoryLos Alamos National LaboratoryDespite 30 years of effort, we do not have an effective HIV-1 vaccine. Over the past decade, the HIV-1 vaccine field has shifted emphasis toward antibody-based vaccine strategies, following a lack of efficacy in CD8+ T-cell-based vaccine trials. Several lines of evidence, however, suggest that improved CD8+ T-cell-directed strategies could benefit an HIV-1 vaccine. First, T-cell responses often correlate with good outcomes in non-human primate (NHP) challenge models. Second, subgroup studies of two no-efficacy human clinical vaccine trials found associations between CD8+ T-cell responses and protective effects. Finally, improved strategies can increase the breadth and potency of CD8+ T-cell responses, direct them toward preferred epitopes (that are highly conserved and/or associated with viral control), or both. Optimized CD8+ T-cell vaccine strategies are promising in both prophylactic and therapeutic settings. This commentary briefly outlines some encouraging findings from T-cell vaccine studies, and then directly compares key features of some T-cell vaccine candidates currently in the clinical pipeline.http://dx.doi.org/10.1080/21645515.2019.1666957hiv vaccinesconserved region vaccinesmosaicscd8+ t cellsimmunotherapy |
| spellingShingle | Bette Korber Will Fischer T cell-based strategies for HIV-1 vaccines Human Vaccines & Immunotherapeutics hiv vaccines conserved region vaccines mosaics cd8+ t cells immunotherapy |
| title | T cell-based strategies for HIV-1 vaccines |
| title_full | T cell-based strategies for HIV-1 vaccines |
| title_fullStr | T cell-based strategies for HIV-1 vaccines |
| title_full_unstemmed | T cell-based strategies for HIV-1 vaccines |
| title_short | T cell-based strategies for HIV-1 vaccines |
| title_sort | t cell based strategies for hiv 1 vaccines |
| topic | hiv vaccines conserved region vaccines mosaics cd8+ t cells immunotherapy |
| url | http://dx.doi.org/10.1080/21645515.2019.1666957 |
| work_keys_str_mv | AT bettekorber tcellbasedstrategiesforhiv1vaccines AT willfischer tcellbasedstrategiesforhiv1vaccines |